Этамбутол

Quick links

Choose a section

Quick links to important sections

Advertisements

Этамбутол

Advertisements
Advertisements

Treatment option: Tuberculosis

Advertisements

Overview of Этамбутол

Property Description
Active Ingredient Ethambutol Hydrochloride
Form Oral Tablet
Pharmacological Class Antitubercular Agent (Antimycobacterial)
General Purpose To halt the multiplication of mycobacteria
Origin Synthetic Chemical Compound

Этамбутол: A Synthetic Antitubercular Agent

Этамбутол (Ethambutol) is a synthetic chemical compound that is critically established in global healthcare, classified as a first-line antitubercular agent. This compound is specifically developed to control infections caused by species of Mycobacterium, primarily Mycobacterium tuberculosis. Pharmacological studies confirm that Ethambutol is characterized by a specific bacteriostatic effect, meaning its core purpose is to stop the growth and prevent the further reproduction of the mycobacteria, rather than actively killing them. The drug is universally recognized for its function in multi-drug protocols, where its unique mechanism of action is essential for preventing the emergence of drug resistance against other antibiotics used in the regimen.


Composition, Form, and General Purpose

The medication’s active substance is Ethambutol Hydrochloride, which is the sole chemical component responsible for the drug’s intended therapeutic effect. As a matter of pharmaceutical design, Этамбутол is formulated and administered as a solid oral tablet for convenient, consistent systemic delivery. The structure is based on an ethylene diamine derivative, confirming its fully synthetic origin. The general therapeutic purpose of Этамбутол is the control and sustained management of active mycobacterial infections, whether they manifest in the lungs or other organs. Its therapeutic effect is founded on the drug’s ability to specifically inhibit the synthesis of arabinogalactan, which is an indispensable structural component of the mycobacterial cell wall. This function is clinically recognized for its reliable ability to arrest the growth of the causative organisms, which is necessary for reducing the bacterial load and enabling successful long-term control of the infection.

Advertisements

What side effects are possible with Этамбутол?

The official documentation of Ethambutol Hydrochloride establishes a safety profile characterized by the risk of specific, often dose and duration-related, adverse reactions impacting multiple physiological systems. This information is classified according to regulatory standards and reflects patterns observed in clinical use.

The most critical and frequently cited adverse reaction is Optic Neuritis

, a condition affecting the eye's optic nerve. According to regulatory classifications, this is categorized as Uncommon and may present as decreased visual acuity, color blindness, visual field defect, and eye pain. This effect is documented as being associated with the dose and duration of treatment, and while generally reversible upon prompt discontinuation, the effects may in rare cases be delayed or irreversible.

Systemic Adverse Reactions

The drug is associated with Severe Cutaneous Adverse Reactions (SCARs), classified as serious and potentially life-threatening. These include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), noted as Very Rare or of Not Known frequency in official labeling.

Ethambutol has also been linked to Hepatobiliary Disorders, with reports of hepatitis, jaundice, and, in very rare instances, hepatic failure. Gastrointestinal disturbances such as nausea, vomiting, and abdominal pain are noted, though the frequency is often classified as Not Known.

Adverse effects involving the Metabolic and Nutrition Disorders system include Hyperuricemia (uncommon), an elevation of uric acid levels, which can lead to attacks of Gout (very rare).

Safety Constraints and Special Populations

Specific safety considerations are documented for certain populations. The drug is contraindicated in patients with known Optic Neuritis and in individuals who are unable to reliably notice or report changes in their vision (e.g., very young children). Toxic effects are officially noted as more common if renal function is impaired due to decreased drug excretion, highlighting the importance of cautious use in this population.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information addresses the clinical signs and necessary emergency actions required in the event of an Ethambutol overdose.

Overdose manifestations documented in labeling primarily affect the visual and nervous systems. Reported symptoms include reduced visual acuity, color vision disturbances (inability to distinguish red and green), headache, mental confusion, and gastrointestinal distress such as vomiting and abdominal pain.

Severe outcomes officially noted include the potential for irreversible blindness due to optic neuropathy and the risk of hepatic failure. Patients with decreased renal function are noted to be at increased risk of overdose-related optic neuropathy due to drug accumulation.

Mandated Emergency Actions:

Contact Emergency Services immediately if the person has experienced a seizure, collapsed, is experiencing trouble breathing, or cannot be awakened. Urgent medical attention is also required for any sudden changes in vision or the onset of color vision disturbances.

Official Management Notes:

  • No specific antidote is known for Ethambutol overdose.
  • Management is strictly symptomatic and supportive, involving procedures such as gastric lavage and potentially haemodialysis to assist in drug elimination, as documented in official regulatory texts.
  • The drug must be stopped immediately in cases where optic neuropathy is observed.
Advertisements

Therapeutic Uses of Этамбутол

Этамбутол (Ethambutol) is a commonly used medication in combination therapy that is applied to help manage and control the bacteria that contribute to Tuberculosis (TB). Its therapeutic role is exclusively relevant for managing active infections caused by the Mycobacterium genus, including both active TB disease (pulmonary and extrapulmonary forms) and Nontuberculous Mycobacterial (NTM) pulmonary disease such as that caused by Mycobacterium avium complex (MAC).


Management of Active Tuberculosis and Mycobacterial Disease

The primary goal of its use is to support the body in gaining control over the underlying pathogen and address severe, systemic manifestations like chronic fever, profuse night sweats, and unintentional weight loss. Therapeutic management of the infection is relevant for easing these debilitating constitutional symptoms and helps ease the burden of chronic respiratory distress, including persistent cough and chest discomfort. The practical application contributes to easing the overall symptom load and supports the patient in maintaining functional stability.


Supporting Treatment of Drug Resistance and Complex Cases

Furthermore, Этамбутол is considered relevant when managing complex clinical scenarios, notably Multidrug-resistant TB (MDR-TB), by playing a role in regimens that aim to limit the development of drug resistance to companion medications. Its inclusion may be part of symptomatic management in complex scenarios such as disseminated or difficult-to-treat infections.


Quick Fact: Relief for Systemic Imbalance Этамбутол is used to help address symptoms related to systemic imbalance and heightened physiological activity, such as persistent fever and night sweats, by addressing the underlying mycobacterial disease.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Ethambutol is strictly defined by regulatory documents, primarily focusing on visual capacity and kidney function.

Category Official Regulatory Status
Populations for whom use is contraindicated Patients with known hypersensitivity to Ethambutol or with known optic neuritis [Source 1.2, 2.5].
Patients who are unable to appreciate and report visual changes (e.g., young children or unconscious patients) [Source 2.5].
Age-related eligibility rules Pediatric: Not recommended for use in patients under 13 years of age (US FDA) due to safe conditions for use not being established [Source 2.5].
Condition-specific eligibility rules Renal Impairment: Requires dosage reduction and increased monitoring, as the drug is primarily cleared by the kidneys, and impairment increases the risk of toxicity [Source 1.1, 1.3].
Pregnancy and lactation eligibility status Pregnancy: US FDA Category C (Use only if benefit justifies potential risk) [Source 2.5]. Other global authorities may classify it as generally acceptable [Source 1.1].
Lactation: Ethambutol is excreted into human milk. Use is not recommended by some regulatory bodies unless the benefit outweighs the risk [Source 1.1, 2.5].

Use is conditional for patients with pre-existing visual defects (e.g., cataracts) or gouty arthritis, necessitating close monitoring. The profile requires eligible patients to be capable of immediate visual reporting to ensure safe use.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The most clearly defined drug interaction involving Ethambutol is with a specific class of acid-reducing agents: aluminum-containing antacids.

Interacting Product Category Specific Interacting Agent Interaction Mechanism
Aluminum-containing antacids Aluminum Hydroxide Impairment of Ethambutol's oral absorption through cation binding in the gastrointestinal tract.

Coadministration of Ethambutol with aluminum hydroxide-containing antacids leads to a measurable reduction in the mean serum concentration of Ethambutol. This decrease in systemic exposure could potentially reduce the effectiveness of the Ethambutol regimen.

Interaction Management and Restrictions

To minimize this pharmacokinetic interaction, it is a key management practice to strictly avoid concurrent administration of Ethambutol and aluminum hydroxide-containing antacids. Regulators typically recommend a separation of at least 4 hours between taking Ethambutol and taking the aluminum-containing antacid.

If medication is required for the management of excess stomach acid, patients are advised to consult with a healthcare professional regarding the use of acid-suppressing drugs or antacids that do not contain aluminum hydroxide. This single, time-dependent interaction constitutes the major, officially recognized interaction constraint on Ethambutol therapy.

Advertisements

Mechanism of Action

️ How Этамбутол Works


Selective Inhibition of Cell Wall Synthesis

The primary mechanism involves the highly specific, noncompetitive inhibition of key mycobacterial enzymes, such as EmbB, which are essential arabinosyltransferases. These enzymes are responsible for the polymerization of D-arabinofuranose, a building block for the Arabinogalactan (AG) layer. By blocking this molecular step, Этамбутол directly prevents the pathogen from synthesizing the structural components necessary for its protective cell wall.


Structural Disruption and Bacteriostasis

The failure to properly construct the AG layer leads to a major structural defect in the cell wall, resulting in increased cellular permeability and metabolic disruption. This mechanistic cascade produces a bacteriostatic effect, meaning the drug halts the growth and reproduction of actively multiplying Mycobacterium species, thereby arresting the expansion of the bacterial population. This disruption is also a key mechanistic factor for synergy, as the compromised cell wall enhances the entry of companion anti-mycobacterial agents.

Advertisements

Dosage and Administration Information

Ethambutol is administered exclusively via the oral route as a film-coated tablet, and its official usage protocol strictly forbids its use as monotherapy; it must be administered as part of a structured, multi-drug regimen. Tablets may be taken with or without food as the active substance's absorption is not clinically impacted by meal timing. The standard administration pattern is defined by duration and dosage, which is based on body weight.

The primary dosage is calculated per kilogram of body weight and follows a phased approach. The initial intensive phase often requires a higher dose, such as 25 mg/kg once daily. This dose is subsequently reduced to a standard 15 mg/kg once daily for the continuation phase. The overall treatment course is protracted, often lasting six to nine months or longer, based on the specific clinical protocol employed.

Dosing frequency is typically once daily, although intermittent regimens, such as two or three times per week, are officially documented alternatives. Dose modification is a required procedural step for specific populations. Patients with renal impairment require mandatory modification, typically involving an extension of the dosing interval (e.g., to every 48 hours) to avoid systemic accumulation. Pediatric dosing is also weight-based, generally in the 15 -25 mg/kg once daily range.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ethambutol

1. Evidence for Use in Active Tuberculosis (TB) Disease

The research base for Ethambutol in active Tuberculosis is well-documented, largely relying on decades of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews research exploring the use of Ethambutol as a component of standard first-line regimens. Researchers primarily examined microbiological endpoints, such as tracking the time it takes for the infection-causing bacteria to clear (sputum culture conversion).

Reports from long-standing treatment programs and major trials describe measurements of treatment completion and cure rates across wide patient populations. Studies described patterns related to the presence of Ethambutol and the occurrence of resistance to companion antibiotics. Despite its established use, few recent RCTs directly compare contemporary regimens to the historical standard, meaning comparative data between different current protocols are limited.


2. Evidence for Use in Nontuberculous Mycobacterial (NTM) Pulmonary Disease

The research for NTM infections, such as those caused by Mycobacterium avium complex (MAC), largely relies on Observational Cohort Studies and detailed Outcome Analyses. These studies evaluate multi-drug regimens where Ethambutol is included alongside other agents. The main study outcomes examined include measuring the rate of achieving a sustained period of negative cultures (culture conversion).

Observational reports described that the time required to achieve a microbiological response can vary significantly among individuals. Some analyses describe patterns where recurrence rates remained high following the completion of treatment, prompting further research. What remains uncertain is whether a two-drug or three-drug protocol is evaluated as better, which remains a subject of ongoing research.


3. Evidence in Special Populations and Uncertainties

Ethambutol was studied for use in certain populations where the standard approach may need adjustment. Research includes pharmacokinetic and pharmacodynamic studies in children, as well as investigations into protocols for patients with HIV co-infection. Data for certain groups, such as those with specific organ function impairments, remain less characterized, and results should only be applied to the populations that were specifically studied.

The overall research landscape, while well-documented for TB, includes areas where research is still developing. Evidence for NTM disease is considered moderate, relying heavily on data from observational programs rather than foundational RCTs. Furthermore, the long-term effects are not fully established for all outcomes, particularly regarding recurrence and sustained control of NTM infection.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Этамбутол (FAQ)


Q: Why is my doctor adding Этамбутол to my existing medication regimen?

Этамбутол is indicated for use only in combination with other anti-tuberculosis agents. It is added to multi-drug regimens primarily to help prevent the infection-causing bacteria from developing resistance to the other companion drugs being used in the treatment.

Q: How often do people get eye problems when on Этамбутол treatment?

Optic neuritis, the most critical adverse eye reaction, is typically classified in regulatory information as uncommon (occurring in 0.1% to 1% of users). Official sources also note that toxicity is highly related to the dose and duration of treatment, with the incidence of vision problems rising significantly at higher doses.

Q: Do I need special eye exams while I'm taking Этамбутол?

Official prescribing information indicates that an ophthalmic (eye) examination is usually performed before starting treatment and periodically throughout the therapy, often monthly. This exam typically includes tests to check for visual acuity, color discrimination, and field of vision to monitor for early changes.

Q: Can Этамбутол cause nerve damage or tingling sensations in the hands and feet?

Adverse events reported in official documentation have included nervous system disorders such as peripheral neuritis, a type of nerve damage outside the brain and spinal cord, which may lead to paresthesia (tingling or numbness). These are generally classified as rare.

Q: What happens if a dose of Этамбутол is missed?

Missing doses can potentially increase the risk of the bacteria developing resistance and may reduce the overall effectiveness of the prescribed therapy. For guidance on managing a missed dose, official recommendations typically describe taking the dose if less than 12 hours have passed, or omitting it if more than 12 hours have passed, before resuming the regular schedule.

Q: Does drinking alcohol affect the safety or effectiveness of Этамбутол?

Regulatory documents do not list a direct drug-alcohol interaction. However, Этамбутол has been associated with liver-related adverse reactions, including hepatitis. Due to the potential for increased stress on the liver, the topic of alcohol consumption should be reviewed with a healthcare professional.

Q: Are there any common foods or supplements that interact with Этамбутол?

The primary recognized interaction is with antacids containing aluminum hydroxide, which can impair the drug's absorption and reduce its effectiveness. No other common foods or non-aluminum supplements are consistently highlighted in official regulatory information as having a major interaction.

Q: Is it safe to take pain relievers like Tylenol (paracetamol) with Этамбутол?

Этамбутол has been associated with a risk of liver toxicity, including hepatitis. Because pain relievers like Paracetamol (acetaminophen) can also affect the liver, official guidance notes that the combination with other potentially liver-toxic medications should be reviewed by a healthcare professional to manage potential risks.

Q: What should I do if the side effects from Этамбутол feel severe?

Official documentation instructs that a healthcare professional must be contacted immediately if any severe side effect is experienced. This includes symptoms such as blurred or changed vision, fever, a generalized skin rash, or signs of liver problems like jaundice (yellowing of the skin or eyes). For life-threatening reactions, emergency medical help must be sought.

Q: Is fatigue a normal side effect when starting Этамбутол?

A general feeling of being unwell (malaise) or unusual tiredness (fatigue) has been reported with the use of Этамбутол, though the frequency is often classified as uncommon or not known. It is important to know that fatigue may also be a symptom of a more serious adverse effect, such as liver damage.

Q: Is there a risk of the infection becoming resistant to Этамбутол?

Yes, regulatory documents indicate that if Этамбутол were used alone (monotherapy), there would be a risk of the bacteria developing resistance to it. This is why the drug is always used as part of a combination regimen. Not adhering to the prescribed schedule can also increase the risk of resistance.

Q: Is it normal to feel a bit dizzy or lightheaded after taking Этамбутол?

Dizziness has been reported as an adverse event associated with the use of Этамбутол, typically classified as very rare in regulatory summaries. Patients who experience dizziness or other neurological side effects are advised to exercise caution with activities like driving.

Q: Can Этамбутол interact with birth control pills?

Regulatory documents do not consistently list a significant interaction between Этамбутол and hormonal birth control pills (oral contraceptives). It is important that all medications being taken are disclosed to the healthcare provider for a comprehensive review.

Q: Does Этамбутол require a specific diet while taking it?

According to official administration instructions, the tablets may be taken with or without food, as absorption of the active substance is generally not affected by meal timing. No specific dietary requirements or restrictions are consistently mandated in the main regulatory documents.

Q: Are there any long-term effects of taking Этамбутол that I should know about?

The most critical potential long-term effect is the risk of irreversible vision loss (optic neuritis), which may occur if the drug is not stopped promptly after visual changes begin. Patients with impaired kidney function may also have an increased risk of long-term toxicity due to decreased drug clearance.

Q: Can Этамбутол interact with common medications for high blood pressure?

Regulatory documents do not consistently list a major, direct drug interaction between Этамбутол and common medications used for high blood pressure. It is important that a full list of current prescriptions is reviewed by a healthcare provider.

Q: Is a metallic taste in the mouth reported by users of Этамбутол?

A metallic taste in the mouth (dysgeusia) is listed as a reported gastrointestinal disorder adverse event in official documentation. The frequency of this effect is typically classified as 'Not Known' based on available data.

Q: Why is the dosage of Этамбутол sometimes adjusted based on weight or kidney function?

Official dosing guidelines state that the primary dose is calculated based on body weight to achieve the correct therapeutic concentration. Dosage modification is also mandatory for patients with impaired kidney function because the drug is primarily cleared by the kidneys, and impairment increases the risk of the drug accumulating in the body and causing toxicity.

Q: Can the drug be crushed or split if the patient has difficulty swallowing pills?

Regulatory documents describe the drug as an oral tablet but do not typically provide explicit instructions regarding crushing, splitting, or alternative administration methods. Options for patients who have difficulty swallowing tablets must be discussed with a healthcare professional or pharmacist.

Q: Why is Этамбутол considered bacteriostatic, not bactericidal, at certain doses?

The primary function of Этамбутол is bacteriostatic, meaning its core purpose is to stop the growth and prevent the further reproduction of the bacteria. It achieves this by halting the synthesis of the mycobacterial cell wall. The goal is to arrest the expansion of the bacterial population, often relying on the body's immune system and companion drugs to eliminate the arrested bacteria.

Advertisements

How should Этамбутол be stored and disposed of?

Official Ethambutol Storage and Disposal Requirements

Scope Element Official Regulatory Requirements
Labeled Storage Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F).
Environmental Protection Protect from light and moisture. The medication must be kept from freezing and away from excess heat.
Packaging Requirements Keep the medicine in the original container and ensure the container is tightly closed and has a child-resistant closure. Do not use if the original seal is broken.
Child Safety Storage Mandatory to keep out of the reach and sight of children.
Disposal Instructions Unused or expired tablets must be disposed of in accordance with local regulations. Medicines should not be discarded via wastewater or household waste.

Connection to the overall storage/disposal profile

Regulatory documentation defines strict stability conditions for Ethambutol tablets, requiring storage within a controlled temperature range and mandatory protection from light and moisture. The official labeled packaging must be a tightly closed, light-resistant container that is kept inaccessible to children. Disposal instructions explicitly require that expired or unused product be handled according to local, regional, or national pharmaceutical waste guidelines, prohibiting disposal in the general household waste stream.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Этамбутол found in:

A-Z Index: